CANADIAN HEALTH CARE PRACTICE 4TH EDITION
BY KARA SEALOCK, CYDNEE SENEVIRATNE
,TABLE OF CONTENTS
CHAPTER 01: NURSING PRACTICE IN CANADA AND DRUG THERAPY ........................................................... 4
CHAPTER 02: PHARMACOLOGICAL PRINCIPLES ............................................................................................ 9
CHAPTER 03: LEGAL AND ETHICAL CONSIDERATIONS ................................................................................ 15
CHAPTER 04: PATIENT-FOCUSED CONSIDERATIONS .................................................................................. 21
CHAPTER 05: GENE THERAPY AND PHARMACOGENOMICS ....................................................................... 33
CHAPTER 06: MEDICATION ERRORS: PREVENTING AND RESPONDING ..................................................... 36
CHAPTER 07: PATIENT EDUCATION AND DRUG THERAPY .......................................................................... 42
CHAPTER 08: OVER-THE-COUNTER DRUGS AND NATURAL HEALTH PRODUCTS ....................................... 48
CHAPTER 09: VITAMINS AND MINERALS .................................................................................................... 54
CHAPTER 10: PRINCIPLES OF DRUG ADMINISTRATION .............................................................................. 61
CHAPTER 11: ANALGESIC DRUGS ................................................................................................................ 72
CHAPTER 12: GENERAL AND LOCAL ANAESTHETICS ................................................................................... 81
CHAPTER 13: CENTRAL NERVOUS SYSTEM DEPRESSANTS AND MUSCLE RELAXANTS ............................... 87
CHAPTER 14: CENTRAL NERVOUS SYSTEM STIMULANTS AND RELATED DRUGS ....................................... 93
CHAPTER 15: ANTIEPILEPTIC DRUGS .......................................................................................................... 99
CHAPTER 16: ANTIPARKINSONIAN DRUGS ............................................................................................... 105
CHAPTER 17: PSYCHOTHERAPEUTIC DRUGS............................................................................................. 111
CHAPTER 18: SUBSTANCE MISUSE ............................................................................................................ 120
CHAPTER 19: ADRENERGIC DRUGS ........................................................................................................... 129
CHAPTER 20: ADRENERGIC-BLOCKING DRUGS ......................................................................................... 138
CHAPTER 21: CHOLINERGIC DRUGS .......................................................................................................... 144
CHAPTER 22: CHOLINERGIC-BLOCKING DRUGS ........................................................................................ 150
CHAPTER 23: ANTIHYPERTENSIVE DRUGS ................................................................................................ 156
CHAPTER 24: ANTIANGINAL DRUGS ......................................................................................................... 162
CHAPTER 25: HEART FAILURE DRUGS ....................................................................................................... 171
CHAPTER 26: ANTIDYSRHYTHMIC DRUGS ................................................................................................ 180
CHAPTER 27: COAGULATION MODIFIER DRUGS ...................................................................................... 186
CHAPTER 28: ANTILIPEMIC DRUGS ........................................................................................................... 192
CHAPTER 29: DIURETIC DRUGS ................................................................................................................. 201
CHAPTER 30: FLUIDS AND ELECTROLYTES ................................................................................................ 207
CHAPTER 31: PITUITARY DRUGS ............................................................................................................... 213
CHAPTER 32: THYROID AND ANTITHYROID DRUGS .................................................................................. 219
,CHAPTER 33: ANTIDIABETIC DRUGS ......................................................................................................... 228
CHAPTER 34: ADRENAL DRUGS ................................................................................................................. 237
CHAPTER 35: WOMEN’S HEALTH DRUGS ................................................................................................. 243
CHAPTER 36: MEN’S HEALTH DRUGS........................................................................................................ 252
CHAPTER 37: ANTIHISTAMINES, DECONGESTANTS, ANTITUSSIVES, AND EXPECTORANTS ..................... 261
CHAPTER 38: RESPIRATORY DRUGS .......................................................................................................... 267
CHAPTER 39: ACID-CONTROLLING DRUGS ............................................................................................... 273
CHAPTER 40: ANTIDIARRHEAL DRUGS AND LAXATIVES ........................................................................... 279
CHAPTER 41: ANTIEMETIC AND ANTINAUSEA DRUGS ............................................................................. 288
CHAPTER 42: NUTRITIONAL SUPPLEMENTS ............................................................................................. 294
CHAPTER 43: ANTIBIOTICS PART 1: SULFONAMIDES, PENICILLINS, CEPHALOSPORINS, MACROLIDES, AND
TETRACYCLINES ......................................................................................................................................... 300
CHAPTER 44: ANTIBIOTICS PART 2: AMINOGLYCOSIDES, FLUOROQUINOLONES, AND OTHER DRUGS... 306
CHAPTER 45: ANTIVIRAL DRUGS ............................................................................................................... 312
CHAPTER 46: ANTITUBERCULAR DRUGS................................................................................................... 321
CHAPTER 47: ANTIFUNGAL DRUGS ........................................................................................................... 327
CHAPTER 48: ANTIMALARIAL, ANTIPROTOZOAL, AND ANTHELMINTIC DRUGS ....................................... 336
CHAPTER 49: ANTI-INFLAMMATORY AND ANTIGOUT DRUGS ................................................................. 342
CHAPTER 50: IMMUNOSUPPRESSANT DRUGS ......................................................................................... 348
CHAPTER 51: IMMUNIZING DRUGS AND PANDEMIC PREPAREDNESS ..................................................... 353
CHAPTER 52: ANTINEOPLASTIC DRUGS PART 1: CANCER OVERVIEW AND CELL CYCLE–SPECIFIC DRUGS
.................................................................................................................................................................. 359
CHAPTER 53: ANTINEOPLASTIC DRUGS PART 2: CELL CYCLE–NONSPECIFIC AND MISCELLANEOUS DRUGS
.................................................................................................................................................................. 365
CHAPTER 54: BIOLOGICAL RESPONSE–MODIFYING DRUGS AND ANTIRHEUMATIC DRUGS .................... 372
CHAPTER 55: ANEMIA DRUGS................................................................................................................... 378
CHAPTER 56: DERMATOLOGICAL DRUGS ................................................................................................. 384
CHAPTER 57: OPHTHALMIC DRUGS .......................................................................................................... 390
CHAPTER 58: OTIC DRUGS ........................................................................................................................ 396
, CHAPTER 01: NURSING PRACTICE IN CANADA AND DRUG THERAPY
MULTIPLE CHOICE
1. WHICH IS A JUDGEMENT ABOUT A PARTICULAR PATIENT’S POTENTIAL NEED OR PROBLEM?
A. A GOAL
B. AN ASSESSMENT
C. SUBJECTIVE DATA
D. A NURSING DIAGNOSIS
CORRECT ANSWER>>D
NURSING DIAGNOSIS IS THE PHASE OF THE NURSING PROCESS DURING WHICH A CLINICAL JUDGEMENT
IS MADE ABOUT HOW A PATIENT RESPONDS TO HEATH CONDITIONS AND LIFE PROCESSES OR
VULNERABILITY FOR THAT RESPONSE.
DIF: COGNITIVE LEVEL: KNOWLEDGE
2. THE PATIENT IS TO RECEIVE ORAL FUROSEMIDE (LASIX) EVERY DAY; HOWEVER, BECAUSE THE
PATIENT IS UNABLE TO SWALLOW, HE CANNOT TAKE MEDICATION ORALLY, AS ORDERED. THE NURSE
NEEDS TO CONTACT THE PHYSICIAN. WHAT TYPE OF PROBLEM IS THIS?
A. A “RIGHT TIME” PROBLEM
B. A “RIGHT DOSE” PROBLEM
C. A “RIGHT ROUTE” PROBLEM
D. A “RIGHT MEDICATION” PROBLEM
CORRECT ANSWER>>C
THIS IS A “RIGHT ROUTE” PROBLEM: THE NURSE CANNOT ASSUME THE ROUTE AND MUST CLARIFY THE
ROUTE WITH THE PRESCRIBER. THIS IS NOT A “RIGHT TIME” PROBLEM BECAUSE THE ORDERED
FREQUENCY HAS NOT CHANGED. THIS IS NOT A “RIGHT DOSE” PROBLEM BECAUSE THE DOSE IS NOT
RELATED TO AN INABILITY TO SWALLOW. THIS IS NOT A “RIGHT MEDICATION” PROBLEM BECAUSE THE
MEDICATION ORDERED WILL NOT CHANGE, JUST THE ROUTE.
DIF: COGNITIVE LEVEL: APPLICATION